Peptide harm reduction: difference between revisions
Diff·revision 19 → 20·01:51, 11 Jul 2025
Difference between revision 19 and revision 20 of Peptide harm reduction. 5 lines changed; the page grew by 610 bytes.
| Revision 19 — 21:25, 23 Jun 2025 TrialsTabitha (talk) state the exchange rate and its date 3,975 bytes ±0 | Revision 20 — 01:51, 11 Jul 2025 Chromatokid (talk) add the cross-link to the insurance article 4,585 bytes +610 | ||
|---|---|---|---|
| 35 | What no document addresses is the absence of clinical oversight — no diagnosis, no monitoring, no clinician aware of the exposure if something goes wrong, and no adverse-event reporting route.{{r|ada2024}} That is a structural feature of unregulated supply rather than a documentation gap. See [[Aspiration risk under anaesthesia]] for one concrete instance.{{r|marlatt1996}} | 35 | What no document addresses is the absence of clinical oversight — no diagnosis, no monitoring, no clinician aware of the exposure if something goes wrong, and no adverse-event reporting route.{{r|ada2024}} That is a structural feature of unregulated supply rather than a documentation gap. See [[Aspiration risk under anaesthesia]] for one concrete instance.{{r|marlatt1996}} |
| 36 | 36 | ||
| + | 37 | == The limits of this article == | |
| + | 38 | Harm reduction as a field distinguishes providing information from encouraging a practice. This wiki provides information about documents, methods and compounds, and takes no position on whether anyone should obtain material outside regulated supply.{{r|marlatt1996}} | |
| + | 39 | ||
| + | 40 | It gives no dosing guidance, describes no preparation intended for administration, and does not evaluate suppliers for suitability. Where handling is described — at [[Reconstitution of lyophilised peptides]], for instance — it is described mechanistically, and the register is deliberately descriptive. | |
| + | 41 | ||
| 37 | == References == | 42 | == References == |
| 38 | {{reflist}} | 43 | {{reflist}} |